# Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

> **NCT05060432** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **iTeos Belgium SA** · enrollment: 153 (actual)

## Conditions studied

- Advanced Cancer
- Lung Cancer
- Head and Neck Cancer
- Melanoma

## Interventions

- **DRUG:** EOS-448
- **DRUG:** pembrolizumab
- **DRUG:** inupadenant
- **DRUG:** Dostarlimab
- **DRUG:** SOC chemotherapies

## Key facts

- **NCT ID:** NCT05060432
- **Lead sponsor:** iTeos Belgium SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-06
- **Primary completion:** 2024-07
- **Final completion:** 2025-07
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060432, "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05060432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*